Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

导出 OA

翻译打印收藏纠错

作者： Maria R,Abbattista ^[1] ; Stephen M F,Jamieson ; Yongchuan,Gu ; Jennifer E,Nickel ; Susan M,Pullen ; Adam V,Patterson ; William R,Wilson ; Christopher P,Guise

作者单位： a Auckland Cancer Society Research Centre; School of Medical Sciences. ^[1]

关键词 AKR1C3 AKR1C3, aldo-keto reductase 1C3 HCC, hepatocellular carcinoma HCR, hypoxic cytotoxicity ratio Hypoxia Nrf2, NF-E2-related factor-2 POR, NADPH:cytochrome P450 oxidoreductase PR-104 UGT-2B7, UDP-glucuronosyltransferase-2B7 hepatocellular carcinoma hypoxia-activated prodrugs nitrogen mustards sorafenib

主题词动物(Animals);癌, 肝细胞(Carcinoma, Hepatocellular);细胞低氧(Cell Hypoxia);细胞系, 肿瘤(Cell Line, Tumor);女(雌)性(Female);Hep G2细胞(Hep G2 Cells);人类(Humans);肝肿瘤(Liver Neoplasms);小鼠(Mice);小鼠, 近交NOD(Mice, Inbred NOD);小鼠, SCID(Mice, SCID);烟酰胺(Niacinamide);氮芥化合物(Nitrogen Mustard Compounds);苯脲化合物(Phenylurea Compounds);药物前体(Prodrugs);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.1080/15384047.2015.1017171

PMID 25869917

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览77

Cancer biology & therapy

2015年16卷4期

610-22页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Cancer biology & therapy

相似文献

Cancer biology & therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Cancer biology & therapy

相似文献

Cancer biology & therapy

相关期刊

检索历史清除